- Active, not recruiting
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
Updated: Feb 10
CARTITUDE-2
Ciltacabtagene Autoleuce
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Sponsor
ClinicalTrials.gov Identifier: NCT04133636
Official Title: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
First Posted : October 21, 2019
Click here for ClinicalTrials.gov
EHA2022 Oral Presentation
EHA 2022 - HYBRID - JUNE 9-17 - VIENNA
CARTITUDE-2 COHORT B: UPDATED CLINICAL DATA AND BIOLOGICAL CORRELATIVE ANALYSES OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY
COMY 22 - Session 15: Abstract communications
CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 COHORT B
CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.
Abstract 8013
2021 ASCO Annual Meeting
3866 Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1–3 Prior Lines of Therapy: Updated Results from CARTITUDE-2
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster III
Hematology Disease Topics & Pathways:
Biological, Clinical Trials, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinical Research, Diseases, Therapies, Infusion, Lymphoid Malignancies
Monday, December 13, 2021, 6:00 PM-8:00 PM
2910 CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy
Program: Oral and Poster Abstracts
Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Biological, Clinical Trials, Plasma Cell Disorders, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Infusion, Lymphoid Malignancies
Sunday, December 12, 2021, 6:00 PM-8:00 PM
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.
Data from the CARTITUDE program at ASH 2021 will provide data on the earlier use of cilta-cel, with updated results from Cohort A of the Phase 2 CARTITUDE-2 study, which included patients who were refractory to lenalidomide with progressive multiple myeloma after 1-3 lines of therapy (Abstract #3866) and the first data from Cohort B of the Phase 2 CARTITUDE-2 study which enrolled patients following early relapse after initial therapy that included proteasome inhibitors and immunomodulatory drugs (Abstract #2910). Both sets of results will be featured in poster presentations.
OAB-043-Ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma and early relapse after initial therapy: biological correlative analyses and updated clinical results from CARTITUDE-2 Cohort B
OAB-044 Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting antibody-drug conjugate treatment -Adam Cohen
OAB-045 Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory multiple myeloma after 1–3 prior lines of therapy: CARTITUDE-2 Cohort A -Adam Cohen
OAB-062 Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting bispecific antibody treatment -Jesús San-Miguel
#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California
* Ciltacabtagene Autoleuce
- California: University of California San Francisco
- Georgia: Emory University Atlanta
- Illinois: Northwestern University Chicago
- Illinois: University of Chicago
- Indiana: Indiana University Indianapolis
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- Minnesota: Mayo Clinic Rochester Minnesota
- Missouri: Washington University School of Medicine Saint Louis
- New Jersey: Hackensack University Medical Center
- New Jersey: Rutgers Cancer Institute of New Jersey New Brunswick
- New York: Roswell Park Cancer Institute Buffalo
- New York: Memorial Sloan-Kettering Cancer Center New York
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- North Carolina: Levine Cancer Institute Charlotte
- Pennsylvania: University of Pennsylvania Philadelphia
- Pennsylvania: University of Pittsburgh Medical Center
- Texas: Baylor University Medical Center Dallas
- Texas: The University of Texas MD Anderson Cancer Center Houston
- Washington: Fred Hutchinson Cancer Center Seattle
Locations
United States, California
United States, Florida
United States, Georgia
United States, Illinois
United States, Indiana
United States, Maryland
United States, Massachusetts
United States, Minnesota
United States, Missouri
United States, New Jersey
United States, New York
United States, North Carolina
United States, Pennsylvania
United States, Texas
United States, Washington
Europe
France
Germany
Netherlands
Spain
Belgium
Asia
Israel
Saudi Arabia
Singapore
RELATED POSTS
NCT03548207: CARTITUDE-1 - Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in RRMM
A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04181827: CARTITUDE 4 - Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relapsed len ref RRMM
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04923893: CARTITUDE-5 - Phase 3 - VRd f/by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned)
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
NCT05257083: CARTITUDE-6 - Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT NDMM
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible